The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017
eLife · 2024
DOI: 10.7554/elife.90782 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von João Paulo Portela Catani und 18 weiteren Autor:innen. Beteiligte Einrichtung: VIB-UGent Center for Medical Biotechnology, Ghent, Belgium. Hauptthemen laut MEDLINE: Neuraminidase, Influenza A Virus, H3N2 Subtype, Ferrets, Antigens, Viral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Vlaams Instituut voor Biotechnologie.
Abstract (Originalsprache)
Human H3N2 influenza viruses are subject to rapid antigenic evolution which translates into frequent updates of the composition of seasonal influenza vaccines. Despite these updates, the effectiveness of influenza vaccines against H3N2-associated disease is suboptimal. Seasonal influenza vaccines primarily induce hemagglutinin-specific antibody responses. However, antibodies directed against influenza neuraminidase (NA) also contribute to protection. Here, we analysed the antigenic diversity of a panel of N2 NAs derived from human H3N2 viruses that circulated between 2009 and 2017. The antigenic breadth of these NAs was determined based on the NA inhibition (NAI) of a broad panel of ferret and mouse immune sera that were raised by infection and recombinant N2 NA immunisation. This assessment allowed us to distinguish at least four antigenic groups in the N2 NAs derived from human H3N2 viruses that circulated between 2009 and 2017. Computational analysis further revealed that the amino acid residues in N2 NA that have a major impact on susceptibility to NAI by immune sera are in proximity of the catalytic site. Finally, a machine learning method was developed that allowed to accurately predict the impact of mutations that are present in our N2 NA panel on NAI. These findings have important implications for the renewed interest to develop improved influenza vaccines based on the inclusion of a protective NA antigen formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.
- Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
- Gnomixx, Melle, Belgium.
- VIB Bioinformatics Core, Ghent, Belgium.
- Sanofi, Research North America, Cambridge, United States.
ORCID-Profile: João Paulo Portela Catani, Janick Mathys, Alexander Botzki, Irina V Ustyugova, Xavier Saelens, Thorsten U Vogel
Förderung
- Sanofi
- Vlaams Instituut voor Biotechnologie
Zitieren
APA
Catani, J. P. P., Smet, A., Ysenbaert, T., Vuylsteke, M., Bottu, G., Mathys, J., Botzki, A., Cortes-Garcia, G., Strugnell, T., Gomila, R., Hamberger, J., Catalan, J., Ustyugova, I. V., Farrell, T., Stegalkina, S., Ray, S., LaRue, L., Saelens, X., & Vogel, T. U. (2024). The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017. eLife. https://doi.org/10.7554/elife.90782
Vancouver
Catani JPP, Smet A, Ysenbaert T, Vuylsteke M, Bottu G, Mathys J, et al. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017. eLife. 2024. doi:10.7554/elife.90782
BibTeX
@article{Catani2024,
author = {Catani, João Paulo Portela and Smet, Anouk and Ysenbaert, Tine and Vuylsteke, Marnik and Bottu, Guy and Mathys, Janick and Botzki, Alexander and Cortes-Garcia, Guadalupe and Strugnell, Tod and Gomila, Raul and Hamberger, John and Catalan, John and Ustyugova, Irina V and Farrell, Timothy and Stegalkina, Svetlana and Ray, Satyajit and LaRue, Lauren and Saelens, Xavier and Vogel, Thorsten U},
title = {The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.90782}
}
EUVIMED